Vigabatrin: Lessons Learned From the United States Experience.

Area of Science:

• Neurology
• Ophthalmology

Background:

• Vigabatrin is an antiseizure medication approved in the US in 2009 with a black box warning for visual loss risk.
• A drug registry was mandated to monitor visual deficits associated with vigabatrin use.

Purpose of the Study:

• To assess visual deficits in patients using vigabatrin.
• To evaluate the incidence of new visual findings and changes in visual pathways during vigabatrin therapy.

Main Methods:

• Analysis of data from the vigabatrin drug registry.
• Prospective, longitudinal, single-arm, open-label vigabatrin vision study in adult patients with refractory complex partial seizures.

Main Results:

• A significant percentage (37%) of patients had preexisting visual deficits at baseline.
• A low percentage (2%) of potential new visual findings were documented.
• An increase in retinal thickness was observed on optical coherence tomography during the first year of vigabatrin therapy.

Conclusions:

• The study highlights the high prevalence of baseline visual deficits in patients treated with vigabatrin.
• Vigabatrin therapy appears to have a low incidence of new visual deficits, though retinal changes warrant further investigation.
• Baseline ophthalmological assessment is crucial for evaluating potential drug toxicity involving visual pathways.